Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iterum Therapeutics (ITRM) EBITDA (2017 - 2022)

Historic EBITDA for Iterum Therapeutics (ITRM) over the last 6 years, with Q4 2022 value amounting to -$7.9 million.

  • Iterum Therapeutics' EBITDA fell 1606.38% to -$7.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$30.4 million, marking a year-over-year decrease of 2382.52%. This contributed to the annual value of -$24.8 million for FY2024, which is 3483.69% up from last year.
  • Iterum Therapeutics' EBITDA amounted to -$7.9 million in Q4 2022, which was down 1606.38% from -$7.0 million recorded in Q3 2022.
  • Iterum Therapeutics' EBITDA's 5-year high stood at -$4.6 million during Q4 2020, with a 5-year trough of -$31.0 million in Q3 2019.
  • In the last 5 years, Iterum Therapeutics' EBITDA had a median value of -$8.2 million in 2020 and averaged -$13.3 million.
  • As far as peak fluctuations go, Iterum Therapeutics' EBITDA plummeted by 20118.13% in 2018, and later skyrocketed by 7996.38% in 2020.
  • Over the past 5 years, Iterum Therapeutics' EBITDA (Quarter) stood at -$23.9 million in 2018, then increased by 3.2% to -$23.2 million in 2019, then skyrocketed by 79.96% to -$4.6 million in 2020, then crashed by 47.05% to -$6.8 million in 2021, then decreased by 16.06% to -$7.9 million in 2022.
  • Its EBITDA was -$7.9 million in Q4 2022, compared to -$7.0 million in Q3 2022 and -$8.0 million in Q2 2022.